Definium Therapeutics, Inc.
DFTX- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- SEC CIK
- 0001813814
In the last 90 days, Definium Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 362 institutions reported holding it in 13F filings for Q2 2026, worth $5.35B in total; Duquesne Family Office is the only superinvestor holding it.
Holders of 5% or more of DFTX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Definium Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 8.30%6.07M shares | – | Feb 5, 20251 filing | Feb 5, 2025 | SEC |
| Deep Track Capital, LP | 13G/A | 6.87%5.50M shares | −1.32 ppfrom 8.19% | May 15, 20252 filings | Nov 14, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
3 Schedule 13D and 13G filings on Definium Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 14, 20258:19 AM ET | Deep Track Capital, LPand 2 others | 13G/A | 6.87%5.50M shares | −1.32 ppfrom 8.19% | Sep 30, 2025 | SEC |
| May 15, 20258:43 AM ET | Deep Track Capital, LPand 2 others | 13G/A | 8.19%6.50M shares | – | Mar 31, 2025 | SEC |
| Feb 5, 20255:28 PM ET | BlackRock, Inc. | 13G/A | 8.30%6.07M shares | – | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Definium Therapeutics, Inc. shares.
No Form 144 notices for Definium Therapeutics, Inc. are on file.